Sign inJoin waitlistJoin the waitlist

Ahmed Elkhanany

Assistant Professor · Baylor College of Medicine

Credentials: · · · · · ·

History

Baylor College of Medicine
Present

Roswell Park Comprehensive Cancer Center
2016–2019
Internal Medicine
University of Missouri at Kansas City
2013–2016
ALEXANDRIA UNIV, ALEXANDRIA
2007–2011

Research

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 914 citations
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
Journal of the National Comprehensive Cancer Network · 2020 · 371 citations
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo
International Journal of Cancer · 2013 · 93 citations

Erica Stringer-Reasor
4 papers
Kazuaki Takabe
3 papers
Allison Kurian
2 papers
Barbara Norquist
2 papers
CM
Carolyn Menendez
2 papers
CK
Catherine Klein
2 papers
CL
Christine Laronga
2 papers
Ciara O'Sullivan
2 papers
Gabrielle Rocque
2 papers
Gwen Reiser
2 papers
Halle Moore
2 papers
Holly Pederson
2 papers

Clinical trials

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Site PI · Recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2026–2031
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Site PI · Recruiting · Phase 2
Ana C Garrido-Castro, MD
2024–2038
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Site PI · Recruiting · Phase 3
LeonaBio
2023–2028